Literature DB >> 2462020

Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2',3'-cyclic nucleotide 3'-phosphodiesterase in the CNS of adult rats.

C Brunner1, H Lassmann, T V Waehneldt, J M Matthieu, C Linington.   

Abstract

In a light and electron microscopic immunocytochemical study we have examined the distribution of myelin basic protein (MBP), 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP), and myelin/oligodendroglial glycoprotein (MOG) within CNS myelin sheaths and oligodendrocytes of adult Sprague-Dawley rats. Ultrastructural immunocytochemistry allowed quantitative analysis of antigen density in different myelin and oligodendrocyte zones: MBP was detectable in high density over the whole myelin sheath, but not in regions of loops, somata, or the oligodendrocyte plasma membrane. CNP reactivity was highest at the myelin/axon interface, and found in lower concentration over the outer lamellae of myelin sheaths, at the cytoplasmic face of oligodendrocyte membranes, and throughout the compact myelin. MOG was preferentially detected at the extracellular surface of myelin sheaths and oligodendrocytes and in only low amounts in the lamellae of compacted myelin and the myelin/axon border zone. Our studies, thus, indicate further the presence of different molecular domains in compact myelin, which may be functionally relevant for the integrity and maintenance of the myelin sheath.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2462020     DOI: 10.1111/j.1471-4159.1989.tb10930.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  81 in total

Review 1.  Maintenance and loss of self-tolerance in B cells.

Authors:  A Iglesias
Journal:  Springer Semin Immunopathol       Date:  2001-12

2.  Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more.

Authors:  Marie Cathrin Mayer; Edgar Meinl
Journal:  Ther Adv Neurol Disord       Date:  2012-05       Impact factor: 6.570

3.  Antibody-mediated demyelination in experimental allergic encephalomyelitis is independent of complement membrane attack complex formation.

Authors:  S Piddlesden; H Lassmann; I Laffafian; B P Morgan; C Linington
Journal:  Clin Exp Immunol       Date:  1991-02       Impact factor: 4.330

4.  The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement.

Authors:  S J Piddlesden; H Lassmann; F Zimprich; B P Morgan; C Linington
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

5.  Ultrastructure of telencephalic myelinated fibers of the hypokinesic rat.

Authors:  M G Zhvaniya; I M Kakabadze
Journal:  Neurosci Behav Physiol       Date:  1996 May-Jun

6.  Degradation products of myelin-oligodendrocyte-associated proteins in a light CNS subcellular fraction.

Authors:  H Persson
Journal:  Neurochem Res       Date:  1991-10       Impact factor: 3.996

7.  Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy.

Authors:  Nadia Stefanova; Markus Reindl; Manuela Neumann; Christian Haass; Werner Poewe; Philipp J Kahle; Gregor K Wenning
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

8.  Redox regulation of cytokine-mediated inhibition of myelin gene expression in human primary oligodendrocytes.

Authors:  Malabendu Jana; Kalipada Pahan
Journal:  Free Radic Biol Med       Date:  2005-09-15       Impact factor: 7.376

9.  Physical mapping of the human and mouse MOG gene at the distal end of the MHC class Ib region.

Authors:  D Pham-Dinh; E P Jones; G Pitiot; B Della Gaspera; P Daubas; J Mallet; D Le Paslier; K Fischer Lindahl; A Dautigny
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

10.  Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ.

Authors:  H Lassmann; C Bancher; H Breitschopf; J Wegiel; M Bobinski; K Jellinger; H M Wisniewski
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.